Last updated: 3 months ago
RedHill Biopharma's Game-Changer: RHB-102 Licensing Deal with Hyloris
Explore RedHill Biopharma's strategic licensing agreement for RHB-102, targeting a $7.5B antiemetics market. Key insights on financial terms, product details, and market impact.